Fusion Pharmaceuticals Inc.
FUSN · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $2 | $1 | $1 | $0 |
| % Growth | 41.5% | 1.5% | – | – |
| Cost of Goods Sold | $1 | $59 | $56 | $0 |
| Gross Profit | $1 | -$57 | -$55 | -$0 |
| % Margin | 35% | -3,931.1% | -3,813.7% | – |
| R&D Expenses | $69 | $59 | $56 | $17 |
| G&A Expenses | $31 | $31 | $27 | $21 |
| SG&A Expenses | $31 | $31 | $27 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | -$2 | $0 | -$32 |
| Operating Expenses | $100 | $89 | $83 | $38 |
| Operating Income | -$99 | -$88 | -$82 | -$38 |
| % Margin | -4,798.5% | -6,025.6% | -5,695.5% | – |
| Other Income/Exp. Net | $5 | -$1 | $1 | -$38 |
| Pre-Tax Income | -$94 | -$89 | -$81 | -$76 |
| Tax Expense | $1 | -$2 | -$0 | $3 |
| Net Income | -$95 | -$88 | -$81 | -$78 |
| % Margin | -4,588.8% | -5,996.7% | -5,628.3% | – |
| EPS | -1.45 | -2 | -1.9 | -3.56 |
| % Growth | 27.5% | -5.3% | 46.6% | – |
| EPS Diluted | -1.45 | -2 | -1.9 | -3.56 |
| Weighted Avg Shares Out | 66 | 44 | 43 | 22 |
| Weighted Avg Shares Out Dil | 66 | 44 | 43 | 22 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10 | $2 | $0 | $0 |
| Interest Expense | $5 | $2 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $1 | $7 |
| EBITDA | -$88 | -$87 | -$81 | -$31 |
| % Margin | -4,235.9% | -5,972.8% | -5,651.5% | – |